The IGIA team are experienced drug development professionals. Lois Rosenberger, PhD is the President and owner of LBR Regulatory-Clinical Consulting Services (LBR) and Acting CEO of IGIA Pharmaceutics. LBR is a niche Contract Research Organization (CRO) that will be used by IGIA Pharmaceuticals to administer the Phase 2 drug development program for dasatinib.

This innovative business model has the advantages of using the expertise and successful track record of senior level professionals. Being a niche CRO LBR will develop dasatinib as a priority and can provide cost effective services.